03:12:08 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Opsens Inc
Symbol OPS
Shares Issued 89,868,817
Close 2018-09-20 C$ 0.88
Market Cap C$ 79,084,559
Recent Sedar Documents

Opsens develops resting pressure measurement product

2018-09-20 09:50 ET - News Release

Mr. Louis Laflamme reports

OPSENS - NEW PRODUCT FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST

Opsens Inc. has developed a product that will allow the diagnosis of coronary heart blockages with the heart at rest. Filing for regulatory approvals has been completed in targeted territories. Opsens plans to begin commercialization by the end of calendar 2018.

In recent years, the measurement of fractional flow reserve (FFR) as a method of assessing intracoronary pressure has gained credibility and popularity following the publication of clinical studies demonstrating its benefits for patients' health. FFR is used to assess the incidence of coronary artery stenosis before selecting a treatment. This measurement is done in the context where the heart is stimulated with the injection of medication. In addition to this interest in FFR, cardiologists have also shown interest in measuring intracoronary pressure to make a diagnosis with the heart at rest, without injection of medication.

Medical publications have highlighted the equivalence of several algorithms using the measurement of pressure at rest. These publications are expected to accelerate the adoption of resting pressure measurement methods in the interventional cardiology community.

This new product, named dPR, will be Opsens's resting pressure measurement method. It will be available through the OptoMonitor and will work in combination with the OptoWire.

With strong intellectual property, Opsens has the potential for significant market share capture through product innovation and differentiation from current electric wires. The FFR market currently stands at approximately $500-million (U.S.).

About Opsens Inc.

Opsens focuses mainly on the measure of FFR and dPR (diastolic pressure ratio) in interventional cardiology. Opsens offers an advanced optical-based pressure guide wire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fibre optic pressure guide wire designed to provide the lowest drift in the industry and excellent lesion access.

Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.